U.S. Markets closed

The Zacks Analyst Blog Highlights: Sanofi, Regeneron, Amgen, InterMune and XOMA

Zacks Equity Research

For Immediate Release
 
Chicago, IL – March 13, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (SNY-Free Report), Regeneron (REGN-Free Report), Amgen (AMGN-Free Report), InterMune (ITMN-Free Report) and XOMA Corporation (XOMA-Free Report).
 
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Biogen Stock Roundup

Late last week, companies developing PCSK9 inhibitors saw a fall in their share price with the FDA raising concerns about this class of drugs. PCSK9 inhibitors work by inhibiting PCSK9, a protein that reduces the liver's ability to remove "bad" cholesterol from the blood.

Although statins (the current standard of treatment) are effective, many patients have problems achieving their cholesterol goals. Moreover, several patients are unable to tolerate statin therapy. In such a scenario, the successful development of PCSK9 inhibitors would be a major breakthrough in the area of cholesterol management. While results on PCSK9 inhibitors in development have been encouraging so far, this is the first time that serious safety concerns have been raised.

The FDA has raised concerns about neurocognitive adverse events in the PCSK9 inhibitor class. These are events that are also associated with the use of statins. So will PCSK9 inhibitors eventually prove to be better than statins as was assumed before?

Sanofi (SNY-Free Report) and Regeneron (REGN-Free Report), who are developing PCSK9 inhibitor alirocumab, disclosed that they have been advised by the FDA regarding the issues though neither company is aware of the circumstances under which the FDA became aware of these adverse events.  So questions like did the FDA notice these events when the PCSK9 inhibitor was being tested as a monotherapy or when it was being tested in combination with a statin or another cholesterol treatment remain.

These companies have been told to evaluate potential neurocognitive adverse events across the global development program for the experimental drug, especially in long-term studies. The FDA has also raised the possibility of incorporating neurocognitive testing in at least a subset of patients in late-stage studies.

With the news about the FDA’s concerns spreading like wildfire, Regeneron saw its shares sliding 3.1%. Amgen’s (AMGN-Free Report) shares were down 1.6%. Amgen’s PCSK9 inhibitor, evolocumab, is currently in late-stage development with regulatory filing expected this year itself. The FDA will most likely ask all these companies to evaluate neurocognitive adverse events in long-term studies.

InterMune (ITMN-Free Report) Soars on Takeover Rumors: InterMune shares were up 10.8% on rumors that it is an acquisition target. The acquisition rumors do not come as a surprise; just a few days back, InterMune scored a huge win in a late-stage study conducted on its lung disease drug, Esbriet. The results are compelling enough for the company to succeed in gaining FDA approval for the product which is already approved in the EU.

Approval in the U.S. would boost sales of the drug significantly. Esbriet sales were $70.3 million in 2013. Given Esbriet’s improving prospects, quite a few pharma companies would be interested in acquiring the company.

Pipeline Setback Overshadows XOMA Corporation’s (XOMA-Free Report) Fourth Quarter Results: XOMA’s fourth quarter results were overshadowed by the company’s announcement that it will not be moving gevokizumab into phase III studies for erosive osteoarthritis of the hand. Shares were down 27.8%.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
 
Get the full Report on SNY - FREE
Get the full Report on REGN - FREE
Get the full Report on AMGN - FREE
Get the full Report on ITMN - FREE
Get the full Report on XOMA - FREE
 
Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
 
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

 
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Read the analyst report on SNY

Read the analyst report on REGN

Read the analyst report on AMGN

Read the analyst report on ITMN

Read the analyst report on XOMA


Zacks Investment Research